Į	648
---	-----

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE nger the Paperwork Reduction Act of 1995, no persons a required to respond to a collection of information unless it displays a valid OMB control number. 09/515,014 Application Number TRANSMITTAL February 29, 2000 Filing Date **FORM** First Named Inventor Patrick F. Coleman et al. (to be used for all correspondence after initial filing) Art Unit 1648 **Examiner Name** R. Budens Total Number of Pages in This Submission Attorney Docket Number 5 02558P-002010US ENCLOSURES (Check all that apply) After Allowance Communication to Drawing(s) Fee Transmittal Form Appeal Communication to Board of Licensing-related Papers Fee Attached Appeals and Interferences Petition Appeal Communication to Group Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Terminal Disclaimer Other Enclosure(s) Extension of Time Request (please identify below): Request for Refund Return Postcard and PTO Form 1449 Express Abandonment Request and Search Report CD, Number of CD(s) Information Disclosure Statement RECEIVED The Commissioner is authorized to charge any additional fees to Certified Copy of Priority Deposit Account 20-1430. Remarks Document(s) APR 0 2 7003 Response to Missing Parts/ Incomplete Application TECH CENTER 1600/2900 Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Townsend and Townsend and Crew LLP Firm Reg. No. 32,928 Brian W. Poor Individual Signature

24 March 2003

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: 74, 2033

Typed or printed Angelie Rivera Date Signature March 24, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Date



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Asst. Commissioner of Patents and Trademarks, Washington, D.C. on

By: myelie

PATENT Attorney Docket No.02558P-002010US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Patrick F. Coleman et al.

Application No.: 09/515,014

Filed: February 29, 2000

For: SYNTHETIC ANTIGEN FOR THE

DETECTION OF ANTIBODIES IMMUNOREACTIVE WITH HIV

**VIRUS** 

Examiner:

R. Budens

Art Unit:

1648

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

RECEIVED

APR 0 2 2003

Assistant Commissioner for Patents Washington, D.C. 20231

TECH CENTER 1600/2900

Dear Sir:

Applicants direct the Examiner's attention to the references below that have been recently cited in a Search Report in a corresponding foreign application. The references listed on the accompanying Form PTO-1449 and copies of the newly cited references are enclosed. Also enclosed is a copy of the European Search Report.

The following U.S. Patents are set forth below by issue date.

AM. U.S. Patent No. 5,075,211 issued on 12/24/91 to Cosand.

The following articles are set forth by the indicated year of publication date:

AN. Hickman et al., "Detection and Differentiation of HIV-1 group O sera from HIV-1 Group M and HIV-2 Using Recombinant Antigens and Peptides," *J. Virol. Meth.* 72:43-49 (1998).

AO. Monji N. et al., "Sensitive and Specific Hiv-1/HIV-2 EIA Using Env and Pol Synthetic Peptdies," *Biosis* Database Accession No. PREV199698616393 XP001105703 (1995).

Patrick Coleman et al. Application No.: 09/515,014 Page 2

- AP. Monji Nobuo et al., "Specific and Sensitive HIV-1/HIV-2 EIA Using Env and Pol Synthetic Peptides," *Biosis* Database Accession No. PREV199598347548 XP001105443 (1995).
- AQ. Ivanov V. et al., "Study of the Antigenic Structure of Human Immunodeficiency Viruses by Means of Synthetic Peptides," *Biosis* Database Accession No. PREV199294121790, X002213768 (1992)
- AR. D.E. Pollet et al., "Confirmation and Differentiation of Antibodies to Human Immunodeficiency Virus 1 and 2 with a Strip-Based Assay Including Recombinant Antigens and Synthetic Peptides" *Clin. Chem.* 37:1700-1707 (1991).
- AS. Sprengers et al., "A MicroELISA System for the Detection of Both Anti-HIV-1 and Anti-HIV-2Antibodies," *J. Immunol. Meth.* 139:77-82 (1991).
- AT. Wain-Hobson et al., "Nucleotide Sequence of the Aids Virus, LAV," *Cell* 10:9-17 (1988).
- AU. Sternberg et al., "Prediction of Antigenic Determinants and Secondary Structures of the Major AIDS Virus Proteins," <u>FEBS Lett.</u> 218:231-237 (1987).

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicants believe that their invention as claimed is patentable over the above references taken alone or in any combination. However, Applicants reserve the right to demonstrate that their claimed invention was made prior to any one or more of the above-identified references. As provided for by 37 C.F.R. § 1.97 (g) and (h), no inference should be drawn as to the pertinence of the references based on the order in which they are presented.

Applicants respectfully request that the Examiner review the foregoing references to make his own determination of the patentability of the present invention and that the references be made of record in the file of this application. This Information Disclosure Statement is being filed before the mailing date of the final Office Action or Notice of Allowance.

<u>PATENT</u> 02558P-002010US

## **CERTIFICATION**

I hereby certify that each item of information contained in this Information

Disclosure Statement was first cited in any communication from a foreign patent office in

counterpart foreign application not more than three months prior to the filing of this statement.

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Dated: 24 March 2003

Brian W. Poor

Reg. No. 32,928

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, CA 94111 Ph.:(206) 467-9600

Fax: (415) 576-0300

1

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

stitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 09/515,014 **Application Number** RECEIVED February 29, 2000 Filing Date Patrick F. Coleman et al. First Named Inventor 1648 Art Unit **Examiner Name** R. Budens

(use as many sheets as necessary)

02558P-2-1US Attorney Docket Number Sheet of

			U.S. PATE	NT DOCUMEN	TS				
Examiner	Cite	Document Number  Number Kind Code <sup>2</sup> (if known)	Publication Da		e of Patentee or t of Cited Document	Pages, Columns, Line Relevant Passages o	r Relevant		
cxammer	No.1		12/24/91		Cosand	Figures Appear			
	AM	5,075,211	12/24/91		Cosano				
			EODEIGN DA	TENT DOCUM	ENTS				
1		Foreign Patent Docu	Foreign Patent Document			Pages, Columns,			
Examiner Cite No.1		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>6</sup> (if known)		Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cite Document		evant _6		
		OTHER PRIOR	ART NON P	ATENT LITER	ATURE DOCUM	ENTS			
Examiner Initials *									
	AN	Hickman et al., "Detection and Differentiation of HIV-1 group O sera from HIV-1 Group M and HIV-2 Using Recombinant Antigens and Peptides," <u>J. Virol. Meth.</u> 72:43-49 (1998).							
	AO	Monji N. et al., "Sensitive and Specific Hiv-1/HIV-2 EIA Using Env and Pol Synthetic Peptdies," <u>Biosis</u> Database Accession No. PREV199698616393 XP001105703 (1995).							
	AP	Monji Nobuo et al., "Specific and Sensitive HIV-1/HIV-2 EIA Using Env and Pol Synthetic Peptides,"  Biosis Database Accession No. PREV199598347548 XP001105443 (1995).							
	AQ	Ivanov V. et al., "Study of the Antigenic Structure of Human Immunodeficiency Viruses by Means of Synthetic Peptides," <i>Biosis</i> Database Accession No. PREV199294121790, X002213768 (1992)							
	AR	D.E. Pollet et al., "Confirmation and Differentiation of Antibodies to Human Immunodeficiency Virus 1 and 2 with a Strip-Based Assay Including Recombinant Antigens and Synthetic Peptides" <u>Clin. Chem.</u> 37 1700-1707 (1991).							
	AS	Sprengers et al., "A MicroELISA System for the Detection of Both Anti-HIV-1 and Anti-HIV-2Antibodies," <i>J. Immunol. Meth.</i> 139:77-82 (1991).							
	AT Wain-Hobson et al., "Nucleotide Sequence of the Aids Virus, LAV," <u>Cell</u> 10:9-17 (1988).								
	1	Sternberg et al., "Prediction of Antigenic Determinants and Secondary Structures of the Major AIDS							
	AU	Virus Proteins," <u>FEBS Lett.</u> 218 P231-237 (1987).							
Examine	r			Date					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Signature

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.